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CASE REPORT
Ruptured aortic aneurysm due 
to Mycobacterium bovis BCG with a delayed 
bacteriological diagnosis due to false negative 
result of the MPB 64 immunochromatographic 
assay
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Abstract 
Background: Adjuvant therapy with bacillus Calmette–Guerin (BCG), a live attenuated strain of Mycobacterium bovis, 
has become the treatment of choice for low-risk superficial bladder carcinoma following transurethral resection of the 
bladder. Complications following vesical BCG instillations are uncommon but, in some cases, severe side-effects can 
occur such as sepsis or mycotic aneurysm. Besides usual laboratory techniques used for the diagnosis of Mycobacte-
rium tuberculosis complex (MTBC) infections (smear microscopy and cultures), commercial immunochromatographic 
assays detecting MBP64, a 24 kDa M. tuberculosis complex-specific secretory protein, can rapidly distinguish MTBC and 
non-tuberculosis mycobacteria (NTM). MPB64 is found in M. tuberculosis, M. bovis and some but not all substrains of 
M.bovis BCG. Therefore, these immunochromatographic tests can lead to false negative results and delayed bacte-
riological diagnosis depending on the presence or absence of MPB64 protein in BCG substrains used for intravesical 
therapy.
Case presentation: We report the case of a 78-year-old male patient who was admitted to the hospital because of a 
1-month history of unexplained fever, thrill, weight-loss and general malaise. His past medical history was marked by 
a non-muscle-invasive bladder carcinoma treated by transurethral resection followed by BCG instillations (Oncotice, 
Merck, USA). The patient was initially treated for a urinary tract infection but as fever persists after 72 h of antibiother-
apy, urinary tract ultrasound was performed and revealed a large abdominal aortic aneurysm confirmed by com-
puted tomography. Surgery was performed after multidisciplinary discussion. Direct smear of perioperative samples 
revealed acid-fast bacilli and both solid and liquid cultures were massively positive. Rapid identification of the positive 
mycobacterial culture was performed using an immunochromatographic assay based on the detection of the Myco-
bacterium tuberculosis MPB 64 antigen. The result was negative for Mycobacterium tuberculosis complex. After review 
of the medical record, a polymerase chain reaction (PCR) was performed and gave a positive result for M. tuberculosis 
complex. Anti-tuberculosis therapy was started immediately and the patient evolved favorably.
Conclusions: Through this case, we showed how the utilisation of MPB64 immunochromatographic assays can 
provide misleading information due to the variable presence of this protein among the different BCG strains. This case 
further illustrates the utility of rapid TB complex-specific PCR assays which provide a more reliable identification of all 
MTBC species.
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(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
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Background
The treatment of choice for low-risk superficial blad-
der carcinoma consists of transurethral resection of the 
bladder (TURB) followed by intravesical chemotherapy. 
For high-risk tumours, adjuvant therapy with BCG has 
become the treatment of choice as it prevents the recur-
rence and delays disease progression [1]. Mechanism of 
action of BCG therapy in this particular indication is not 
fully understood but it seems that the local inflammation 
induced by these instillations could result in anti-tumor 
effect [2].
Bacillus Calmette–Guerin (BCG) is a live attenuated 
strain of Mycobacterium bovis, which is part of the M. 
tuberculosis complex (MTBC) and principally used as a 
vaccine against human tuberculosis [3]. Since the origi-
nal strain of BCG was characterised in 1921, cumulative 
genetic mutations have progressively appeared, follow-
ing decades of sub-culture and global distribution of the 
strain. This evolution has led to marked differences in the 
phenotype, the antigenicity (including the secretion of 
MBP64 protein) and the clinical characteristics between 
the different vaccinal substrains distributed globally. The 
MBP64 gene is still present among the substrains Tokyo, 
Sweden, Moreau, and Russia, but is missing among the 
substrains Copenhagen, Glaxo, Pasteur and Tice (the 
strain used for the treatment of the patient presented 
below) [4–6].
Complications following BCG instillations or vac-
cinations are uncommon (1–10% of patients) and usu-
ally consist in local reactions (including hypersensitivity 
reactions, abscesses at the injections site and localized 
lymphadenopathy). Severe disseminated infections fol-
lowing vaccination have been reported, but this com-
plication is infrequent and usually linked to severe 
alteration of the immunity [7]. On the other hand, over 
one-third of patients report moderate general symptoms 
(fever, malaise), hematuria, pollakiuria or dysuria follow-
ing BCG bladder instillations. 1–4% of patients further 
present granulomatous prostatitis or epididymo-orchi-
tis. Life-threatening BCG sepsis is uncommon (<1% of 
patients). Mycotic aneurysm is an extremely rare compli-
cation, involving predominantly the aorta. To date, less 
than 30 patients with mycotic aneurysm following intra-
vesical BCG therapy have been reported. Globally, local 
and systemic side-effects result in treatment discontinua-
tion for approximately 20% of patients [8, 9].
In order to prevent systemic complications, BCG instil-
lations are contraindicated during a period of 2  weeks 
following TURB, bladder biopsy, traumatic catheteriza-
tion, urethral stenosis, macroscopic haematuria, prior 
BCG sepsis and urinary tract infection. It is also con-
traindicated in the context of active tuberculosis infec-
tion [10].
In most clinical laboratories, the bacteriological diag-
nosis of M. bovis BCG infections is performed using the 
same laboratory techniques as for MTBC infections, 
including smear microscopy and culture. Among positive 
cultures, the differentiation between MTBC and NTM is 
done using commercial immunochromatographic assays 
detecting the MBP64 antigen in positive cultures [11]. 
In Belgium, direct MTBC PCR is currently not recom-
mended outside particular indications.
We report the case of a patient with a ruptured abdom-
inal mycotic aortic aneurysm following intravesical BCG 
instillation for whom the bacteriological diagnostic was 
delayed due to a false negative result of the BD MGIT 
TBc Identification Test©.
Case presentation
A 78-year-old male patient was admitted to the hospital 
following a 1-month history of unexplained fever, thrill, 
weight-loss and general malaise, and a 1-week complaint 
of pollakiuria.
Twelve years prior to this episode, the patient was diag-
nosed with a non-muscle-invasive bladder carcinoma 
that was treated by transurethral resection followed by 
BCG instillations (Oncotice, Merck, USA). These instil-
lations were repeated after 7, 8 and 11  years due to 
oncological relapse. The last BCG instillation was admin-
istered 5 months before admission.
The medical history of the patient further included 
hypertension, and atrial fibrillation for which he received 
anti-vitamin K therapy. He was in remission of a prostate 
cancer for which he had received radiotherapy and anti-
androgen therapy 4 years earlier.
On admission, clinical examination was unremarkable. 
Laboratory workup revealed inflammation (CRP elevated 
at 5.7 mg/dL), hematuria and leucocyturia. Urine culture 
was positive for Escherichia coli and cefuroxime antibio-
therapy was initiated according to the drug susceptibility 
profile.
As fever was persisting 72 h after initiation of antibiotic 
therapy, a urinary tract ultrasound (US) was performed 
in order to exclude an obstacle or an abcess. US revealed 
a large abdominal aortic aneurysm, which was subse-
quently confirmed by computed tomography (CT). The 
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size of the aneurysm was measured at 7 × 7 × 7.3 cm and 
located in the infra-renal region (Fig. 1). This image was 
not present on a CT performed 3 years earlier. Antibiotic 
therapy was stopped and blood cultures were collected.
Four days after admission, the patient fell during the 
night. A second abdominal CT revealed a large retrop-
eritoneal hematoma but no sign of rupture was observed. 
After multi-disciplinary discussion, the patient under-
went surgery. Perioperative samples were sent to the bac-
teriology laboratory for conventional and mycobacterial 
cultures.
Direct smear of the aneurysm was positive for acid-fast 
bacilli. Direct PCR was not performed, as current Bel-
gian guidelines do not recommend to perform this test 
on non-pulmonary samples. Both liquid cultures (MGIT, 
Becton–Dickinson, Baltimore, MD, USA) and solid cul-
tures (Löwenstein-Jensen media, Beckton Dickison, 
Baltimore, MD, USA) were positive. Following internal 
procedures and the manufacturer’s instructions, rapid 
identification of the positive mycobacterial culture was 
performed using the BD MGIT TBc Identification Test© 
(Beckton Dickinson Diagnostic, USA), an immunochro-
matographic assay based on the detection of the Myco-
bacterium tuberculosis MPB 64 antigen. The result was 
negative for Mycobacterium tuberculosis complex. After 
review of the medical record, BCGosis was suspected, 
and the PCR-based Xpert MTB/Rif assay (Cepheid, USA) 
was performed on the positive culture and gave a positive 
result for M. tuberculosis complex. M.bovis BCG identi-
fication was later confirmed by the Belgian national ref-
erence center which performed a second PCR targeting 
CSB and RD1 [12].
Management of M. bovis mycotic aneurysms include 
both surgical replacement with an aortic graft material 
and 9–12  months antimycobacterial therapy including 
isoniazid, rifampicine and ethambutol [6]. Pyrazinamide 
is not used due to intrinsic resistance of M. bovis to this 
drug. Antimycobacterial therapy decreases the risk of 
relapse following surgery [13].
As a result, anti-tuberculosis therapy with rifampicine, 
ethambutol, isoniazide and pyrazinamide was started in 
our patient. Pyrazinamide was discontinued upon defini-
tive identification of BCG. After 2  months, ethambutol 
was discontinued and rifampicin and isoniazide were 
pursued for additional 7 months. The patient showed no 
signs of relapse after two-years of follow up. The clinical 
examination and the CT were normal at that time.
Conclusion
Mycotic aneurysm is an extremely rare but life-threaten-
ing complication of intravesical BCG therapy, generally 
involving the aorta [14]. Rapid and accurate diagnosis is 
important to ensure the prompt initiation of the adequate 
treatment. Through this case, we showed how the utilisa-
tion of MPB64 immunochromatographic assays can pro-
vide misleading information due to the variable presence 
of this protein among the different BCG strains. This case 
further illustrates the superiority of rapid TB complex-
specific PCR assays which provide a more reliable iden-
tification of all MTBC species. Following this experience, 
the laboratory has modified its internal procedures, and a 
PCR is now systematically performed for all samples pre-
senting a direct smear or a positive culture. In the latter 
case, the MPB64 immunochromatographic assay is still 
performed in parallel.
MPB64 immunochromatographic still remains, in most 
cases, a useful tool for the differential diagnosis between 
MTBC and NTM infections. The present cases neverthe-
less suggests that this simple assay should be replaced by 
PCR assays for patients presenting a risk of BCG-related 
infection.
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Fig. 1 CT sagittal section performed showing abdominal aortic 
aneurysm. A CT was performed after initial failure of antibiotherapy 
and showed and abdominal aortic aneurysm previously seen on US
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